Esperion Therapeutics Inc. (NASDAQ: ESPR) is 16.46% higher on its value in year-to-date trading and has touched a low of $23.90 and a high of $76.98 in the current 52-week trading range. The ESPR stock was last observed hovering at around $30.28 in the last trading session, with the day’s loss setting it -3.21% off its average median price target of $45.00 for the next 12 months. It is also 85.83% off the consensus price target high of $191.00 offered by 11 analysts, but current levels are 15.41% higher than the price target low of $32.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $27.07, the stock is -6.19% and -5.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.94 million and changing -10.62% at the moment leaves the stock -26.48% off its SMA200. ESPR registered -47.00% loss for a year compared to 6-month loss of -36.15%. The firm has a 50-day simple moving average (SMA 50) of $28.80 and a 200-day simple moving average (SMA200) of $34.74.
The stock witnessed a 4.16% gain in the last 1 month and extending the period to 3 months gives it a -7.15%, and is 5.34% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.50% over the week and 6.98% over the month.
Esperion Therapeutics Inc. (ESPR) has around 193 employees, a market worth around $839.06M and $218.90M in sales. Profit margin for the company is -46.20%. Distance from 52-week low is 13.24% and -64.84% from its 52-week high. The company has generated returns on investments over the last 12 months (-467.80%).
Esperion Therapeutics Inc. (ESPR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Esperion Therapeutics Inc. (ESPR) is a “Overweight”. 11 analysts offering their recommendations for the stock have an average rating of 1.90, where 3 rate it as a Hold and 0 think it is a “Overweight”. 7 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Esperion Therapeutics Inc. is expected to release its quarterly report on 05/12/2021 and quarterly earnings per share for the current quarter are estimated at -$2.76 with sales reaching $41.73M over the same period.The EPS is expected to grow by 52.50% this year, but quarterly earnings will post 75.00% year-over-year. Quarterly sales are estimated to grow 4,149.50% in year-over-year returns.
Esperion Therapeutics Inc. (ESPR) Top Institutional Holders
237 institutions hold shares in Esperion Therapeutics Inc. (ESPR), with 236.95k shares held by insiders accounting for 0.85% while institutional investors hold 123.19% of the company’s shares. The shares outstanding are 27.83M, and float is at 27.59M with Short Float at 36.66%. Institutions hold 122.14% of the Float.
The top institutional shareholder in the company is Bellevue Group AG with over 5.47 million shares valued at $203.16 million. The investor’s holdings represent 19.61% of the ESPR Shares outstanding. As of Dec 30, 2020, the second largest holder is Meditor Group Ltd with 2.68 million shares valued at $69.68 million to account for 9.61% of the shares outstanding. The other top investors are Wasatch Advisors Inc which holds 2.41 million shares representing 8.64% and valued at over $89.57 million, while Vanguard Group, Inc. (The) holds 8.27% of the shares totaling 2.3 million with a market value of $85.65 million.
Esperion Therapeutics Inc. (ESPR) Insider Activity
A total of 2 insider transactions have happened at Esperion Therapeutics Inc. (ESPR) in the last six months, with sales accounting for 0 and purchases happening 2 times. The most recent transaction is an insider purchase by BIOTECH TARGET N V, the company’s 10% Owner. SEC filings show that BIOTECH TARGET N V bought 200,000 shares of the company’s common stock on Nov 03 at a price of $25.31 per share for a total of $5.06 million. Following the purchase, the insider now owns 3.95 million shares.
Esperion Therapeutics Inc. disclosed in a document filed with the SEC on Mar 11 that MAYLEBEN TIMOTHY M (President & CEO) bought a total of 2,500 shares of the company’s common stock. The trade occurred on Mar 11 and was made at $43.00 per share for $0.11 million. Following the transaction, the insider now directly holds 0.11 million shares of the ESPR stock.
Still, SEC filings show that on Feb 28, MAYLEBEN TIMOTHY M (President & CEO) acquired 5,000 shares at an average price of $49.00 for $0.24 million. The insider now directly holds 109,498 shares of Esperion Therapeutics Inc. (ESPR).
Esperion Therapeutics Inc. (ESPR): Who are the competitors?
The company’s main competitors (and peers) include Amicus Therapeutics Inc. (FOLD) that is trading 155.80% up over the past 12 months. Regeneron Pharmaceuticals Inc. (REGN) is 33.47% up on the 1-year trading charts. Short interest in the company’s stock has risen 9.28% from the last report on Nov 29, 2020 to stand at a total of 9.78 million short shares sold with a short interest ratio of 18.27.